Therapy: A local approach to Raynaud phenomenon

Nature Reviews Rheumatology

Volumn 5, Issue 5, 2009, Pages 246-247

  Herrick, Ariane L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; VASODILATOR AGENT;

BLOOD FLOW; DRUG EFFECT; EMULSION; FINGER; HEMODYNAMICS; HUMAN; MICROCIRCULATION; NOTE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; TOPICAL DRUG ADMINISTRATION; VASCULARIZATION;

ADMINISTRATION, TOPICAL; EMULSIONS; FINGERS; HEMODYNAMICS; HUMANS; MICROCIRCULATION; NITROGLYCERIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 67650376148     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.64     Document Type: Article

References (10)

1. Chung, L. et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon. Arthritis Rheum. 60, 870-877 (2009).
2. Kleckner, M. S., Allen, E. V. & Wakim, K. G. The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon: studies on blood flow and clinical manifestations. Circulation 3, 681-689 (1951).
3. Francks, A. G. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet 1, 76-77 (1982).
4. Anderson, M. E. et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxf.) 41, 324-328 (2002).
5. Teh, L. S. et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br. J. Rheumatol. 34, 636-641 (1995).
6. Merkel, P A. et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 46, 2410-2420 (2002).
7. Thompson, A. E. & Pope, J. E. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxf.) 44, 145-150 (2005).
8. Thompson, A. E., Shea, B., Welch, V., Fenlon, D. & Pope, J. E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44, 1841-1847 (2001).
9. Belch, J. et al. MQX-503, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud's phenomenon. Arthritis Rheum. 58 (Suppl.), S622 (2008).
10. Lewis, T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 15, 7-101 (1929)